JB Chemicals & Pharmaceuticals ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, entered into an agreement with Glenmark Pharmaceuticals Ltd to acquire the Razel (Rousvastatin) franchise for the India and Nepal region. The transaction is expected to be closed within next two weeks subject to customary closing formalities.
Rosuvastatin is a lipid-lowering medication (statin). It works by blocking an enzyme, HMG-CoA-reductase that is required by the body to make cholesterol, thereby lowering LDL level and triglycerides and raising good"cholesterol, HDL.
J.B. Pharma established in 1976, is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension and the heart-failure segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country.
The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges.
Commenting on the acquisition, Mr. Nikhil Chopra, CEO and Whole Time Director, JB Pharma said, “We are glad to announce the acquisition of the Razel(Rousvastatin & combinations) franchise from Glenmark Pharmaceuticals, thereby marking JB’s expansion into Statins, which is the largest therapeutic segment in cardiology. With this addition, we now have established strong position in statins besides being among the leaders in Hypertension and Heart failure – all the fastest growing therapeutic indications in cardiology.”
He further added “We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focussed for this segment and further strengthen our chronic portfolio.”
